Stockscreener 앱 받기
0.39
2.38%
-0.0095
시간 외 거래:
.40
0.01
+2.56%
전일 마감가:
$0.3995
열려 있는:
$0.4019
하루 거래량:
869.15K
Relative Volume:
0.14
시가총액:
$5.78M
수익:
$200.00K
순이익/손실:
$-10.95M
주가수익비율:
-0.1976
EPS:
-1.9738
순현금흐름:
$-10.78M
1주 성능:
-13.31%
1개월 성능:
-0.03%
6개월 성능:
-70.68%
1년 성능:
-77.06%
1일 변동 폭
$0.37
$0.4101
1주일 범위
$0.37
$0.4492
52주 변동 폭
$0.28
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
명칭
Soligenix Inc
전화
609-538-8200
주소
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
0.39 | 5.92M | 200.00K | -10.95M | -10.78M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-28 | 다운그레이드 | Dawson James | Buy → Neutral |
| 2018-01-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 재확인 | Maxim Group | Buy |
| 2017-07-17 | 개시 | H.C. Wainwright | Buy |
Soligenix Inc 주식(SNGX)의 최신 뉴스
Soligenix Inc (SNGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Soligenix Inc (SNGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Soligenix Inc (SNGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month On Ebola Vaccine Optimism - Stocktwits
SNGX Stock Price, Quote & Chart - ChartMill
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
Soligenix Inc (SNGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Soligenix Inc (SNGX) Institutional Confidence - TradingKey
Soligenix Inc (SNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Soligenix Inc (SNGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Soligenix Inc (SNGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Soligenix Inc (SNGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Soligenix Q1 2026 Earnings: Narrower-Than-Expected Loss as EPS Beats EstimatesRevenue Breakdown Analysis - newsline.com
Soligenix (SNGX) Hovers Near Key Support After Modest DeclineBearish Pattern Stocks - newsline.com
Soligenix Halts HyBryte Program, Refocuses Pipeline Strategy - TipRanks
Soligenix's Richard C. Straube ceases Consulting CMO role; duties moved to Christopher Pullion - TradingView
Soligenix (NASDAQ: SNGX) faces Nasdaq bid-price risk and ends HyBryte program - Stock Titan
SNGX Q1 2026 Earnings: EPS Beat Amid No Revenue, Stock DeclinesGross Profit Margin - newsline.com
Soligenix (SNGX) Bounces From Support: Biotech Stock Rises 3.5% to $0.44IV Contraction - newsline.com
Soligenix Stock Short Interest Rises to 43.99% - Quiver Quantitative
SNGX Q1 2026 Earnings: Narrower Loss Than Anticipated as Biotech Advances PipelineManagement Guidance Update - newsline.com
Soligenix Announces Recent Accomplishments And Third Quarter 202 - GuruFocus
Soligenix (SNGX) Pursues Vaccine Development for Bundibugyo Viru - GuruFocus
Soligenix (SNGX) stock soars 72% on ThermoVax platform promise amid Ebola outbreak caused by Bundibugyo virus - MSN
Soligenix applies for CEPI funding to develop thermostable vaccine for Bundibugyo Ebola virus. - Pluang
Soligenix (SNGX) Pursues Vaccine Development for Bundibugyo Virus - GuruFocus
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine - Barchart.com
Soligenix (SNGX) Hovers Near Support With Slight DeclineRegression Channel - newsline.com
Soligenix, Inc. Files SEC Form 8-K for May 28, 2026 – Company Information and Legal Exhibits - Minichart
Soligenix Expands At-The-Market Equity Financing Capacity - TipRanks
Soligenixincreases maximum offering under sales agreement by $2.96 million - marketscreener.com
Soligenix raises at‑market share capacity by $2.956M under sales agreement - TradingView
Soligenix (NASDAQ: SNGX) raises at-the-market stock capacity by $2.96M - Stock Titan
Soligenix (NASDAQ: SNGX) raises ATM ceiling to $2.96M under Sales Agreement - Stock Titan
Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX - RTTNews
Soligenix Company Profile & Introduction - Moomoo
Soligenix more than doubles as traders react to Ebola-outbreak vaccine-platform update - Quiver Quantitative
$AIM ImmunoTech (AIM.US)$ easiest money i ever made $Soligenix (SNGX.US)$ you 2 booboo - Moomoo
Soligenix (SNGX) Stock Soars 110% as Ebola Outbreak Puts Vaccine Hopes on the Table - MEXC
SNGX Stock Pops On Heavy Volume As Traders Hunt Volatility - StocksToTrade
Soligenix Stock Nearly Doubles Before the Bell as Ebola Vaccine Hopes Put Tiny Biotech Back in Play - TechStock²
$Soligenix (SNGX.US)$ - Moomoo
Top Premarket Gainers - Moomoo
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy - Yahoo Finance
Trending Stocks Today | Soligenix Soars 133.91% Pre-Market - Moomoo
$Soligenix (SNGX.US)$ checkmate [Share Link: Join us in the TradersLink chat.] - Moomoo
Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo V - Benzinga
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo - Lelezard
Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo Virus - Sahm
$Soligenix (SNGX.US)$ thank - Moomoo
Soligenix (SNGX) Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates, Stock SlipsTop Trending Breakouts - Newser
Soligenix Inc (SNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
1.15%
자본화:
|
볼륨(24시간):